25 January 2026
: Case report 
Histiocytic Sarcoma Treated With Autologous Stem Cell Transplantation: A Case Report and Literature Review of the Role of Autologous and Allogenic Stem Cell Transplantation
Rare disease
Yun Ji Lee
BCDEF 1, Dong Won Baek AF 1*
DOI: 10.12659/AJCR.950225
Am J Case Rep 2026; 27:e950225
Table 2 Clinical outcomes of HS patients undergoing stem cell transplantation.
| Study | Age/Sex | First-line treatment | Initial response | Salvage treatment | Salvage response | Follow-up* (months) | Type of SCT | Clinical outcomes** |
|---|---|---|---|---|---|---|---|---|
| Nam H et al []6 | 48/M | EPOCH 3 cycles | SD | ESHAP 4 cycles | SD | 13.3 | Allo-SCT | Achieved CR alive |
| Nam H et al []6 | 26/M | EPOCH 3 cycles | PD | DL-ICE 1 cycleESHAP 3 cycles | PD | 26.3 | Allo-SCT | Achieved CR alive |
| Nam H et al []6 | 57/F | EPOCH 3 cycles | SD | DL-ICE 2 cycles | SD | 7.3 | Allo-SCT | died due to cerebral hemorrhage |
| Nam H et al []6 | 28/F | CHOEP 6 cycles | CR | DL-ICE 3 cyclesDHAP 3 cyclesEPOCH 2 cycles | PR | 55.5 | Allo-SCT | Achieved CR died due to relapse and progression |
| Tomlin J et al []10 | 33/M | CHOP 3 cycles | PR | ICE, CLAG-M | PR | 9 | Allo-SCT | Achieved CR died due to pneumonia |
| Zeidan A et al []11 | 23/F | CHOPCHOEP 2 cycles | PR | N/A | N/A | 12 | Allo-SCT | Achieved CR alive |
| Huff D et al []12 | 51/F | CHOP-pembrolizumab | CR | ICE-pembrolizumab bridging clofarabine | PD | 26 | Allo-SCT | Achieved CR died due to relapse and progression |
| Gergis U et al []8 | 64/F | Oral thalidomideCHOP 4 cycles | PR | N/A | N/A | 6 | Auto-SCT | Achieved CR alive with maintenance thalidomide |
| Abu-Sanad A et al []13 | 40/F | CHOP 6 cycles | CR | ESHAP 3 cycles | PR | 24 | Auto-SCT | Achieved CR alive |
| Tsujimura H et al []14 | 38/F | CHOP-AVP 3 cycles | CR | N/A | N/A | 30 | Auto-SCT | Achieved CR alive |
| HS – histiocytic sarcoma; CR – complete response; PR – partial response; SD – stable disease; PD – progressive disease; Auto-SCT – autologous stem cell transplantation; Allo-SCT – allogeneic stem cell transplantation; EPOCH – etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin; CHOEP – cyclophosphamide-doxorubicin-vincristine-etoposide-prednisone; ICE, ifosfamide-carboplatin-etoposide; DHAP – dexamethasone-cytarabine-cisplatin; DL-ICE – dose-limited ICE; SCT – stem cell transplantation. * Follow-up duration is calculated from initial diagnosis. ** Clinical outcome represents disease status at the time of last follow-up or death. | ||||||||